OncoMatch/Clinical Trials/NCT07356245
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Is NCT07356245 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Ruxolitinib for t-cell lymphoma.
Treatment: Ruxolitinib — This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "graft" is the donor blood cells that patients get during the transplant. The "host" is the person receiving the cells. GVHD is when the donor graft attacks and damages some of the transplant recipient's tissues. Ruxolitinib is a type of drug called a Janus kinase (JAK) inhibitor which works by decreasing the immune response of cells in the body. It is also a cancer growth blocker that blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene, called JAK2, that is important in the production of cancer cells.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
Biomarker criteria
Excluded: ALK overexpression
Excluded: DUSP22 overexpression
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: hematopoietic stem cell transplant
Cannot have received: systemic therapy post-sct
Exception: radiation allowed
Cannot have received: ruxolitinib
Lab requirements
Blood counts
absolute neutrophil count (anc) > 1000/mm3 without g-csf for at least 3 days, platelets > 50k/mm3 without transfusion for at least 3 days, hemoglobin (hb) > 8.0 g/dl without transfusion for at least 3 days
Kidney function
ckd-epi egfr ≥ 30 ml/min
Liver function
total bilirubin < 1.5 x uln, alanine aminotransferase (alt) <= 3 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07356245 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy post-sct, ruxolitinib disqualifies patients from enrollment.
Are patients with ALK alterations eligible?
No. ALK overexpression is an exclusion criterion.
Are patients with DUSP22 alterations eligible?
No. DUSP22 overexpression is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify